Identification of Novel Epigenetic Markers of Prostate Cancer by NotI-Microarray Analysis

Disease Markers

Volumn 2015, Issue , 2015, Pages

  Dmitriev, Alexey A ^a,b   Rosenberg, Eugenia E ^c   Krasnov, George S ^a   Gerashchenko, Ganna V ^c   Gordiyuk, Vasily V ^c   Pavlova, Tatiana V ^d   Kudryavtseva, Anna V ^a   Beniaminov, Artemy D ^a   Belova, Anastasia A ^a   Bondarenko, Yuriy N ^e   Danilets, Rostislav O ^e   Glukhov, Alexander I ^f   Kondratov, Aleksandr G ^c   Alexeyenko, Andrey ^d   Alekseev, Boris Y ^b   Klein, George ^d   Senchenko, Vera N ^a   Kashuba, Vladimir I ^c,d  

^a ENGELHARDT INSTITUTE OF MOLECULAR BIOLOGY   (Russian Federation)

^b P A Herzen Research Oncological Institute   (Russian Federation)

^c INSTITUTE OF MOLECULAR BIOLOGY AND GENETICS   (Ukraine)

^d KAROLINSKA INSTITUTE   (Sweden)

^e STATE INSTITUTION NATIONAL RESEARCH CENTER FOR RADIATION MEDICINE OF THE NATIONAL ACADEMY OF MEDICAL SCIENCES OF UKRAINE   (Ukraine)

^f KURCHATOV INSTITUTE   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

BISULFITE; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 12; PROTEIN BCL 6; TRANSCRIPTION FACTOR GATA 2; UNCLASSIFIED DRUG; TUMOR MARKER;

ARTICLE; CHROMOSOME 3; CLINICAL ARTICLE; CLONE; DNA METHYLATION; DOWN REGULATION; EPIGENETICS; GENE DELETION; GENE LOCUS; GENETIC ASSOCIATION; HUMAN; MALE; MICROARRAY ANALYSIS; POLYMERASE CHAIN REACTION; PROSTATE BIOPSY; PROSTATE CANCER; QUANTITATIVE ANALYSIS; TUMOR GENE; CASE CONTROL STUDY; DNA MICROARRAY; GENE REGULATORY NETWORK; GENETIC EPIGENESIS; GENETICS; PATHOLOGY; PROSTATE TUMOR;

BIOMARKERS, TUMOR; CASE-CONTROL STUDIES; DNA METHYLATION; EPIGENESIS, GENETIC; GENE DELETION; GENE REGULATORY NETWORKS; HUMANS; MALE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROSTATIC NEOPLASMS;

EID: 84944213103     PISSN: 02780240     EISSN: 18758630     Source Type: Journal    
DOI: 10.1155/2015/241301     Document Type: Article

References (72)

1. J. Ferlay, I. Soerjomataram, M. Ervik et al., GLOBOCAN 2012 v1. 0, Cancer Incidence and Mortality Worldwide: IARC Cancer-Base No. 11, International Agency for Research on Cancer, Lyon, France, 2012, http://globocan. iarc. fr/
2. H. Ahmadi and S. Daneshmand, "Androgen deprivation therapy for prostate cancer: long-termsafety and patient outcomes," Patient Related Outcome Measures, vol. 5, pp. 63-70, 2014
3. M. Katsogiannou, H. Ziouziou, S. Karaki, C. Andrieu, M. H. de Villeneuve, and P. Rocchi, "The hallmarks of castrationresistant prostate cancers," Cancer Treatment Reviews, vol. 41, no. 7, pp. 588-597, 2015
4. A. D. Grigore, E. Ben-Jacob, and M. C. Farach-Carson, "Prostate cancer and neuroendocrine differentiation: more neuronal, less endocrine" Frontiers in Oncology, vol. 5, article 37, 2015
5. V. J. Gnanapragasam, "Molecular markers to guide primary radical treatment selection in localized prostate cancer," Expert Review ofMolecular Diagnostics, vol. 14, no. 7, pp. 871-881, 2014
6. S. M. Nazim and F. Abbas, "Role of surgery in locally advanced prostate cancer," Pakistan Journal ofMedical Sciences, vol. 31,no. 3, pp. 710-716, 2015
7. E. F. Faria, B. F. Chapin,R. L. Muller, R. D. Machado, R. B. Reis, and S. F. Matin, "Radical prostatectomy for locally advanced prostate cancer: current status," Urology, vol. 86, no. 1, pp. 10-15, 2015
8. J. Sullivan, R. Kopp, K. Stratton et al., "An analysis of the association between prostate cancer risk loci, PSA levels, disease aggressiveness and disease-specific mortality," British Journal of Cancer, vol. 113, no. 1, pp. 166-172, 2015
9. M. Danilewicz, O. Stasikowska-Kanicka, and M. Wagrowska-Danilewicz, "Augmented immunoexpression of survivin correlates with parameters of aggressiveness in prostate cancer," Polish Journal of Pathology, vol. 66, no. 1, pp. 44-48, 2015
10. S. I. Berndt, Z. Wang, M. Yeager et al., "Two susceptibility loci identified for prostate cancer aggressiveness," Nature Communications, vol. 6, p. 6889, 2015
11. A. B. Gutman and E. B. Gutman, "An 'acid' phosphatase occurring in the serum of patients with metastasizing carcinoma of the prostate gland,"The Journal of Clinical Investigation, vol. 17, no. 4, pp. 473-478, 1938
12. T. Bhavsar, P. McCue, and R. Birbe, "Molecular diagnosis of prostate cancer: are we up to age" Seminars in Oncology, vol. 40, no. 3, pp. 259-275, 2013
13. H. Y. Kong and J. Byun, "Emerging roles of human prostatic acid phosphatase," Biomolecules and Therapeutics, vol. 21, no. 1, pp. 10-20, 2013
14. R. Chou, J. M. Croswell, T. Dana et al., "Screening for prostate cancer: a review of the evidence for the U. S. Preventive services task force," Annals of Internal Medicine, vol. 155, no. 11, pp. 762-771, 2011
15. M. Ferro, D. Bruzzese, S. Perdonà et al., "Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) significantly improve prostate cancer detection at initial biopsy in a total PSA range of 2-10 ng/ml," PLoS ONE, vol. 8, no. 7,Article ID e67687, 2013
16. E. E. Rosenberg, T. Y. Prudnikova, G. V. Gerashchenko, E. V. Grigorieva, and V. I. Kashuba, "Search for genes-potential markers of aggressiveness and metastasis for human prostate cancer," Biopolymers and Cell, vol. 29, no. 6, pp. 499-505, 2013
17. C. A. Iacobuzio-Donahue, "Epigenetic changes in cancer," Annual Review of Pathology: Mechanisms of Disease, vol. 4, pp. 229-249, 2009
18. R. Singal, L. Ferdinand, I. M. Reis, and J. J. Schlesselman, "Methylation of multiple genes in prostate cancer and the relationship with clinicopathological features of disease," Oncology Reports, vol. 12, no. 3, pp. 631-637, 2004
19. J. Pan,Y. Chen, C. Mo et al., "AssociationofDSC3mRNAdownregulation in prostate cancer with promoter hypermethylation and poor prognosis," PLoS ONE, vol. 9, no. 3,Article ID e92815, 2014
20. J. Sandoval, L. Peiró-Chova, F. V. Pallardó, and J. L. García-Giménez, "Epigenetic biomarkers in laboratory diagnostics: emerging approaches and opportunities," Expert Review of Molecular Diagnostics, vol. 13, no. 5, pp. 457-471, 2013
21. S. H. Strand, T. F. Orntoft, and K. D. Sorensen, "PrognosticDNA methylation markers for prostate cancer," International Journal of Molecular Sciences, vol. 15, no. 9, pp. 16544-16576, 2014
22. K. Daniunaite, S. Jarmalaite, N. Kalinauskaite et al., "Prognostic value of RASSF1 promoter methylation in prostate cancer," Journal of Urology, vol. 192, no. 6, pp. 1849-1855, 2014
23. K. Woodson, K. J. O'Reilly, D. E. Ward et al., "CD44 and PTGS2 methylation are independent prognostic markers for biochemical recurrence among prostate cancer patients with clinically localized disease," Epigenetics, vol. 1, no. 4,pp. 183-186, 2006
24. K. Chiam, C. Ricciardelli, and T. Bianco-Miotto, "Epigenetic biomarkers in prostate cancer: current and future uses," Cancer Letters, vol. 342, no. 2, pp. 248-256, 2014
25. G. Weiss, S. Cottrell, J. Distler et al., "DNA methylation of the PITX2 gene promoter region is a strong independent prognostic marker of biochemical recurrence in patients with prostate cancer after radical prostatectomy," The Journal of Urology, vol. 181, no. 4, pp. 1678-1685, 2009
26. L. Maldonado, M. Brait, M. Loyo et al., "GSTP1 promoter methylation is associated with recurrence in early stage prostate cancer," Journal of Urology, vol. 192, no. 5, pp. 1542-1548, 2014
27. W. Zhang, H. Jiao, X. Zhang et al., "Correlation between the expression of DNMT1, and GSTP1 and APC, and the methylation status of GSTP1 and APC in association with their clinical significance in prostate cancer," Molecular Medicine Reports, vol. 12, no. 1, pp. 141-146, 2015
28. L. Richiardi, V. Fiano, C. Grasso et al., "Methylation of APC and GSTP1 in non-neoplastic tissue adjacent to prostate tumour and mortality from prostate cancer," PLoS ONE, vol. 8, no. 7,Article ID e68162, 2013
29. W. Li, R. Wang, Z. Yan, L. Bai, and Z. Sun, "High accordance in prognosis prediction of colorectal cancer across independent datasets by multi-gene module expression profiles," PLoS ONE, vol. 7, no. 3, Article ID e33653, 2012
30. R. Tsunashima,Y. Naoi,N. Kagara et al., "Construction ofmultigene classifier for prediction of response to and prognosis after neoadjuvant chemotherapy for estrogen receptor positive breast cancers," Cancer Letters, vol. 365, no. 2, pp. 166-173, 2015
31. G. V. Gerashchenko, O. O. Bogatyrova, E. E. Rudenko et al., "Genetic and epigenetic changes of NKIRAS1 gene in human renal cell carcinomas," Experimental Oncology, vol. 32, no. 2, pp. 71-75, 2010
32. V. V. Gordiyuk, "Genetic and epigenetic changes of genes on chromosome 3 in human urogenital tumors," Biopolymers and Cell, vol. 27, no. 1, pp. 25-35, 2011
33. V. I. Kashuba, I. Y. Skrypkina, D. V. Saraev et al., "Identification of changes in gene loci potentially associated with cervical cancer usingNotI microarrays,"Ukrain'skyi Biokhimichnyi Zhurnal, vol. 78, no. 2, pp. 113-120, 2006
34. L. B. Hesson, W. N. Cooper, and F. Latif, "Evaluation of the 3p21. 3 tumour-suppressor gene cluster," Oncogene, vol. 26, no. 52, pp. 7283-7301, 2007
35. G. Ciriello,M. L. Miller, B. A. Aksoy, Y. Senbabaoglu,N. Schultz, and C. Sander, "Emerging landscape of oncogenic signatures across human cancers," Nature Genetics, vol. 45,no. 10, pp. 1127-1133, 2013
36. L. Ji, J. D. Minna, and J. A. Roth, "3p21. 3 tumor suppressor cluster: prospects for translational applications," Future Oncology, vol. 1, no. 1, pp. 79-92, 2005
37. A. J. H. Smith, J. Xian, M. Richardson, K. A. Johnstone, and P. Rabbitts, "Cre-loxP chromosome engineering of a targeted deletion in the mouse corresponding to the 3p21. 3 region of homozygous loss in human tumours," Oncogene, vol. 21, no. 29, pp. 4521-4529, 2002
38. J. Li, A. Protopopov, F. Wang et al., "NotI subtraction and NotI-specific microarrays to detect copy number and methylation changes in whole genomes," Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 16, pp. 10724-10729, 2002
39. T. Maniatis, E. F. Fritsch, and J. Sambrook, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA, 1982
40. T. L. Dunwell, L. B. Hesson, T. Pavlova et al., "Epigenetic analysis of childhood acute lymphoblastic leukemia," Epigenetics, vol. 4, no. 3, pp. 185-193, 2009
41. V. V. Gordiyuk, G. V. Gerashchenko, I. Y. Skrypkina et al., "Identification of chromosome 3 epigenetic and genetic abnormalities and gene expression changes in ovarian cancer," Biopolymers and Cell, vol. 24, no. 4, pp. 323-332, 2008
42. K. Haraldson, V. I. Kashuba, A. A. Dmitriev et al., "LRRC3B gene is frequently epigenetically inactivated in several epithelial malignancies and inhibits cell growth and replication," Biochimie, vol. 94, no. 5, pp. 1151-1157, 2012
43. A. A. Dmitriev, V. I. Kashuba, K. Haraldson et al., "Genetic and epigenetic analysis of non-small cell lung cancer with NotImicroarrays," Epigenetics, vol. 7, no. 5, pp. 502-513, 2012
44. V. N. Senchenko, G. S. Krasnov, A. A. Dmitriev et al., "Differential expression of CHL1 gene during development of major human cancers," PLoS ONE, vol. 6, no. 3, Article IDe15612, 2011
45. G. S. Krasnov, N. Y. Oparina, A. A. Dmitriev et al., "RPN1, a new reference gene for quantitative data normalization in lung and kidney cancer,"Molecular Biology, vol. 45,no. 2, pp. 211-220, 2011
46. C. Campbell and Y. Ying, Learning with Support Vector Machines, Morgan & Claypool Publishers, San Rafael, Calif, USA, 2011
47. R. Nisbet, J. Elder, and G. Miner, Handbook of Statistical Analysis and Data Mining Applications, Academic Press, Burlington, Mass, USA, 2009
48. A. Alexeyenko,W. Lee, M. Pernemalm et al., "Network enrichment analysis: extension of gene-set enrichment analysis to gene networks," BMC Bioinformatics, vol. 13, no. 1, article 226, 2012
49. A. Alexeyenko and E. L. L. Sonnhammer, "Global networks of functional coupling in eukaryotes from comprehensive data integration," Genome Research, vol. 19,no. 6, pp. 1107-1116, 2009
50. M. Kanehisa, S. Goto, S. Kawashima, and A. Nakaya, "The KEGG databases at GenomeNet," Nucleic Acids Research, vol. 30, no. 1, pp. 42-46, 2002
51. A. Ruepp, B. Waegele, M. Lechner et al., "CORUM: the comprehensive resource of mammalian protein complexes-2009," Nucleic Acids Research, vol. 38, pp. D497-D501, 2010
52. A. Subramanian, P. Tamayo, V. K. Mootha et al., "Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles," Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 43, pp. 15545-15550, 2005
53. L. A. Bovolenta, M. L. Acencio, and N. Lemke, "HTRIdb: an open-access database for experimentally verified human transcriptional regulation interactions," BMC Genomics, vol. 13, article 405, 2012
54. E. R. Zabarovsky, R. Gizatullin, R. M. Podowski et al., "NotI clones in the analysis of the human genome," Nucleic Acids Research, vol. 28, no. 7, pp. 1635-1639, 2000
55. G. V. Gerashchenko, V. V. Gordiyuk, I. Y. Skrypkina et al., "Screening of epigenetic and genetic disturbances of human chromosome 3 genes in colorectal cancer," Ukrainski Biokhimicheski Zhurna, vol. 81, no. 4, pp. 81-87, 2009
56. V. N. Senchenko, N. P. Kisseljova, T. A. Ivanova et al., "Novel tumor suppressor candidates on chromosome 3 revealed by NotI-microarrays in cervical cancer," Epigenetics, vol. 8, no. 4, pp. 409-420, 2013
57. A. A. Dmitriev, E. E. Rudenko, A. V. Kudryavtseva et al., "Epigenetic alterations of chromosome 3 revealed by notimicroarrays in clear cell renal cell carcinoma," BioMed Research International, vol. 2014, Article ID 735292, 9 pages, 2014
58. A. G. Kondratov, S. M. Kvasha, L. A. Stoliar et al., "Alterations of the WNT7A gene in clear cell renal cell carcinomas," PLoS ONE, vol. 7, no. 10, Article IDe47012, 2012
59. V. Kashuba, A. A. Dmitriev, G. S. Krasnov et al., "Noti microarrays: novel epigenetic markers for early detection and prognosis of high grade serous ovarian cancer," International Journal of Molecular Sciences, vol. 13, no. 10, pp. 13352-13377, 2012
60. H. Li, Y. Du, D. Zhang et al., "Identification of novel DNA methylation markers in colorectal cancer using MIRA-based microarrays," Oncology Reports, vol. 28, no. 1, pp. 99-104, 2012
61. Z.-Q. Lian, Q. Wang, W.-P. Li, A.-Q. Zhang, and L. Wu, "Screening of significantly hypermethylated genes in breast cancer using microarray-based methylated-CpG island recovery assay and identification of their expression levels," International Journal of Oncology, vol. 41, no. 2, pp. 629-638, 2012
62. J. U. Kang, S. H. Koo, K. C. Kwon, J. W. Park, and J. M. Kim, "Identification of novel candidate target genes, including EPHB3, MASP1 and SST at 3q26. 2-q29 in squamous cell carcinoma of the lung," BMC Cancer, vol. 9, article 237, 2009
63. T. V. Pavlova, V. I. Kashuba, O. V. Muravenko et al., "Use of NotI microarrays in analysis of epigenetic and structural changes in epithelial tumor genomes by the example of human chromosome 3," Molecular Biology, vol. 43, no. 2, pp. 313-320, 2009
64. B. S. Taylor, N. Schultz, H. Hieronymus et al., "Integrative genomic profiling of human prostate cancer," Cancer Cell, vol. 18, no. 1, pp. 11-22, 2010
65. P. Bastola, Y. Stratton, E. Kellner et al., "Folliculin contributes to VHL tumor suppressing activity in renal cancer through regulation of autophagy," PLoS ONE, vol. 8, no. 7, Article ID e70030, 2013
66. M. A. Chetram, D. A. Bethea, V. A. Odero-Marah, A. S. Don-Salu-Hewage, K. J. Jones, and C. V. Hinton, "ROS-mediated activation of AKT induces apoptosis via pVHL in prostate cancer cells," Molecular and Cellular Biochemistry, vol. 376, no. 1-2, pp. 63-71, 2013
67. X.-Y. Yang, X.-G. Lai, Y. Zhang, J.-M. Pei, A.-G. Yang, and S.-S. Zhou, "siRNA-mediated silencing of ClC-2 gene inhibits proliferation of human U-87 glioma cells," Ai Zheng, vol. 25, no. 7, pp. 805-810, 2006
68. C.-Y. Chang, S.-C. Lin, W.-H. Su, C.-M. Ho, and Y.-S. Jou, "Somatic LMCD1 mutations promoted cell migration and tumor metastasis in hepatocellular carcinoma," Oncogene, vol. 31, no. 21, pp. 2640-2652, 2012
69. M. Lehto, S. Laitinen, G. Chinetti et al., "The OSBP-related protein family in humans," The Journal of Lipid Research, vol. 42, no. 8, pp. 1203-1213, 2001
70. R. D. M. Steenbergen, M. Ongenaert, S. Snellenberg et al., "Methylation-specific digital karyotyping of HPV16E6E7-expressing human keratinocytes identifies novel methylation events in cervical carcinogenesis," Journal of Pathology, vol. 231, no. 1, pp. 53-62, 2013
71. K. Miyamoto, T. Fukutomi, S. Akashi-Tanaka et al., "Identification of 20 genes aberrantly methylated in human breast cancers," International Journal of Cancer, vol. 116, no. 3, pp. 407-414, 2005
72. S. Shiraishi, C. Zhou, T. Aoki et al., "TBP-interacting protein 120B (TIP120B)/cullin-associated and neddylation-dissociated 2 (CAND2) inhibits SCF-dependent ubiquitination of myogenin and accelerates myogenic differentiation," Journal of Biological Chemistry, vol. 282, no. 12, pp. 9017-9028, 2007.